Last reviewed · How we verify
Decapinol (DELMOPINOL)
Decapinol (generic name: DELMOPINOL) is a delmopinol drug. It is currently in Phase 2 development for Dental plaque.
Decapinol works by preventing the adhesion of bacteria to tooth surfaces.
Decapinol, also known as delmopinol, is a small molecule drug in the delmopinol class. It is used to treat dental plaque, a condition where bacteria accumulate on teeth. The commercial status of Decapinol is unclear, but it is likely patented. Key safety considerations include unknown half-life and bioavailability. Decapinol is owned by an unknown entity.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DELMOPINOL |
|---|---|
| Drug class | delmopinol |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
This means that Decapinol creates a barrier on the teeth that prevents bacteria from sticking to them, making it harder for plaque to form. This helps to prevent the development of gum disease and other oral health issues.
Approved indications
- Dental plaque
Common side effects
Key clinical trials
- A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis
- Study of an Essential Oil and a Delmopinol Mouthrinse Effect on Dental Plaque Accumulation Index, Gingivitis Index and on Streptococcus Mutans, Lactobacillus, Aerobic and Anaerobic Oral Bacteria Colony Counts. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Decapinol CI brief — competitive landscape report
- Decapinol updates RSS · CI watch RSS
Frequently asked questions about Decapinol
What is Decapinol?
How does Decapinol work?
What is Decapinol used for?
What is the generic name of Decapinol?
What drug class is Decapinol in?
What development phase is Decapinol in?
Related
- Drug class: All delmopinol drugs
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Dental plaque
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing